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A B S T R A C T
Current prescribing practices for major depressive disorder (MDD) produce limited treatment success. Although pharmacogenomics may improve outcomes by
identifying genetically inappropriate medications, studies to date were limited in scope. Outpatients (N= 1167) diagnosed with MDD and with a patient- or
clinician-reported inadequate response to at least one antidepressant were enrolled in the Genomics Used to Improve DEpression Decisions (GUIDED) trial – a rater-
and patient-blind randomized controlled trial. Patients were randomized to treatment as usual (TAU) or a pharmacogenomics-guided intervention arm in which
clinicians had access to a pharmacogenomic test report to inform medication selections (guided-care). Medications were considered congruent (‘use as directed’ or
‘use with caution’ test categories) or incongruent (‘use with increased caution and with more frequent monitoring’ test category) with test results. Unblinding
occurred after week 8. Primary outcome was symptom improvement [change in 17-item Hamilton Depression Rating Scale (HAM-D17)] at week 8; secondary
outcomes were response (≥50% decrease in HAM-D17) and remission (HAM-D17≤7) at week 8. At week 8, symptom improvement for guided-care was not
significantly different than TAU (27.2% versus 24.4%, p= 0.107); however, improvements in response (26.0% versus 19.9%, p= 0.013) and remission (15.3%
versus 10.1%, p= 0.007) were statistically significant. Patients taking incongruent medications prior to baseline who switched to congruent medications by week 8
experienced greater symptom improvement (33.5% versus 21.1%, p= 0.002), response (28.5% versus 16.7%, p=0.036), and remission (21.5% versus 8.5%,
p= 0.007) compared to those remaining incongruent. Pharmacogenomic testing did not significantly improve mean symptoms but did significantly improve re-
sponse and remission rates for difficult-to-treat depression patients over standard of care (ClinicalTrials.gov NCT02109939).
1. Introduction
Major depressive disorder (MDD) is a serious and prevalent illness
that continues to be associated with world-leading morbidity and dis-
ability as determined by the World Health Organization. (Organization,
2017). Current treatment approaches rely primarily on antidepressant
medications and psychotherapy based on clinician's choice, preference,
and experience. Studies consistently document that approximately half
of patients with moderate-to-severe MDD do not respond adequately to
their first medication, as originally shown in the pivotal STAR*D trial
where only 49% of first-episode patients achieved response and 37%
achieved remission after the first line of treatment (Rush et al., 2006b).
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If patients failed to respond to this first intervention, the struggle to
achieve response and remission continued during subsequent medica-
tion trials, with only 13% of patients achieving remission during their
fourth medication (Rush et al., 2006b). Ultimately, current treatment
approaches result in a long duration of unremitted illness for many
patients, which is associated with worsened long-term prognosis (Ghio
et al., 2014), adverse changes in brain function and morphology (Ghio
et al., 2014), increased side-effect burden (Mrazek et al., 2014), in-
tensification of other medical illnesses and corresponding annual
medical costs (Mrazek et al., 2014), increased suicide risk, and adverse
occupational and financial consequences (Greden, 2013; Trivedi et al.,
2013). These data highlight the need for more effective treatment ap-
proaches.
Genetic variation is one of a number of variables that may impact
the efficacy of a medication by affecting its metabolism (pharmacoki-
netics) or mechanism of action (pharmacodynamics). Medication safety
may also be impacted by gene-drug interactions that result in harmful
side-effects (Zhou et al., 2015). Pharmacogenomic assessments emerged
as data-driven strategies to develop a more personalized, precise ap-
proach to antidepressant selection. Available strategies initially con-
sisted of testing for single genes that encode for selected cytochrome
P450 (CYP450) enzymes, which metabolize most psychotropic medi-
cations. As the field evolved, additional genes related to pharmacoki-
netics and pharmacodynamics were investigated. This multi-gene
testing approach continued to utilize individual genotypes to determine
single gene-drug interactions for each evaluated gene (Bradley et al.,
2018; Perez et al., 2017; Singh, 2015). A recent randomized controlled
trial found that multi-gene testing improved response and remission
rates (Bradley et al., 2018) and reduced the economic burden among
patients with very severe depression (n= 93) (Maciel et al., 2018).
While multi-gene tests provide added single genotype information,
they do not assess the combined, interactive effects of multiple genes
and genotypes (Swen et al., 2018). For instance, drugs may be meta-
bolized through multiple pathways such that reduced function in one
gene can be offset by increased function in another. To illustrate, for
citalopram, decreased CYP2D6 function in an individual might be ba-
lanced by increased function of CYP2C19 to result in normal metabo-
lism (Hicks et al., 2015). Depending on the combined phenotype with
CYP2C19, a CYP2D6 poor metabolizer may have normal, lower or
higher exposure to citalopram than population means. To address such
considerations, a pharmacogenomic test was developed to genotype
multiple relevant genes and produce a combined phenotype. The aim
was to weight the genotypes for all measured variants or alleles in order
to rank each medication according to the combined effect of all gene-
drug interactions that impact the efficacy and safety of the drug for an
individual patient (Hall-Flavin et al., 2012). The apparent clinical uti-
lity (Hall-Flavin et al., 2013; Hall-Flavin et al., 2012; Winner, J.G. et al.,
2013), analytical validity (Jablonski et al., 2018), and cost effectiveness
(Brown et al., 2017; Hornberger et al., 2015; (Jablonski et al., 2018,
Winner, J. et al., 2013; Winner et al., 2015) of this weighted and
combined, multi-gene pharmacogenomic test have been shown in pa-
tients with depression who have failed one or more medication.
The number of commercially available pharmacogenomic tests has
grown; however, there are also growing uncertainties and concerns
regarding the clinical utility of such tests (Goldberg, 2017; Rosenblat
et al., 2017; Zeier et al., 2018; Zubenko et al., 2018). The most com-
monly expressed concerns and criticisms have pertained to study de-
sign, as evidence supporting the efficacy of pharmacogenomic testing
has stemmed largely from non-randomized open-label trials or small
randomized trials (Goldberg, 2017; Rosenblat et al., 2017; Zeier et al.,
2018; Zubenko et al., 2018). There also have been concerns regarding
study duration, cohort composition, and the incorporation of a robust
comparator arm (Goldberg, 2017; Rosenblat et al., 2017; Zeier et al.,
2018; Zubenko et al., 2018). Additionally, a recent study of pharma-
cogenomic tests found that there is a high level of disagreement be-
tween tests, suggesting that pharmacogenomic tests are not
interchangeable and likely require separate evaluations to determine
clinical utility (Bousman and Dunlop, 2018).
To concomitantly address many of the expressed study design
concerns while evaluating the utility of pharmacogenomic testing in
patients with MDD, we present data from the Genomics Used to
Improve DEpression Decisions (GUIDED) trial. To the authors’ knowl-
edge, this is the largest, blinded, randomized, long-term, controlled trial
using pharmacogenomic testing for MDD to date. In this trial, active
treatment guided by pharmacogenomic testing was compared to un-
guided active treatment (treatment as usual, TAU) in patients with
MDD who had failed to respond to at least one adequate prior medi-
cation trial. Symptom improvement, response, and remission were
monitored over 24 weeks with the primary endpoint at week 8.
2. Material and methods
2.1. Pharmacogenomic testing
The GeneSight® Psychotropic test from Assurex Health, Inc. (Mason,
OH) was used for pharmacogenomic testing on all patients, as pre-
viously described (Jablonski et.al., 2018). The genotypes of 59 alleles
and variants across 8 genes (CYP1A2, CYP2C9, CYP2C19, CYP3A4,
CYP2B6, CYP2D6, HTR2A, SLC6A4; Supplemental Table 1) were eval-
uated by a pharmacogenomic algorithm. This is a proprietary test based
on licensed technology disclosed in issued patents (U.S. patent no.
8,401,801 and U.S. patent no. 8,688,385). In brief, the algorithm
weighed the combined influence of each individual genotype on patient
response to each individual medication (Hall-Flavin et al., 2012). Based
on this weighted and combined phenotype, 38 psychotropic medica-
tions were categorized based on three levels of gene-drug interaction:
‘use as directed’ (no detected gene-drug interactions), ‘use with caution’
(moderate gene-drug interactions; i.e. medications may be effective
with dose modification), ‘use with increased caution and with more
frequent monitoring’ (severe gene-drug interactions that may sig-
nificantly impact drug safety and/or efficacy).
2.2. Study description
The GUIDED trial was a 24-week, randomized, controlled trial that
evaluated outcomes when a pharmacogenomic test was used to guide
medication selection (guided-care) compared to TAU. The trial protocol
was approved by the Copernicus Group independent review board
(INC1-14-012) and was performed in accordance with the principles of
the Declaration of Helsinki. All patients provided written informed
consent after receiving a complete description of the study.
The full study design is described in the Supplemental Methods. In
brief, patients were enrolled at screening between April 14, 2014 and
February 10, 2017. Eligible patients were randomized 1:1 to TAU or the
guided-care (intervention) arm. Pharmacogenomic testing was per-
formed for all patients between screening and baseline visits.
This trial differed from traditional drug studies in that patients in
both arms received active treatment. For patients in TAU, active
treatment was unguided by pharmacogenomic data. For patients in the
guided-care arm, clinicians had access to the pharmacogenomic test
report prior to the baseline visit to use in medication selection. Patients
and raters were blinded to study arm. Clinicians could not be blinded to
study arm, as the pharmacogenomic test results had to be consulted to
select potential medications for the guided-care arm. Adherence to the
test results was not mandated. For patients in TAU, clinicians were
blinded to the pharmacogenomic test result until after completion of the
week 8 visit. Sites were instructed to unblind patients in both arms after
assessments at week 12 were completed. Because unblinding may have
occurred prior to week 12 assessments, data collected through week 8
were considered blinded.
Patient assessments were performed at weeks 0 (baseline), 4, 8, 12,
and 24. The primary assessment was the 17-item Hamilton Depression
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rating scale (HAM-D17), administered by a blinded central rater
(MedAvante-ProPhase Inc., Hamilton, NJ). Secondary assessments in-
cluded the 16-item Quick Inventory of Depression Symptomology
(QIDS-C16; administered by a blinded site rater) and 9-item Patient
Health Questionnaire (PHQ-9; patient reported). No assessments com-
pleted by the unblinded clinician are included here.
2.3. Participants
Outpatients were enrolled from 60 academic and community sites in
the U.S. that included psychiatric and primary care providers. Patients
were included if they were over the age of 18, were diagnosed with
MDD (≥11 on the QIDS-C16 and self-rated QIDS-SR16 at screening and
baseline) and had an inadequate response (lack of clinical improvement
or intolerable side-effects as reported by the patient or treating clin-
ician) to at least one documented psychotropic treatment included on
the pharmacogenomic test report within the current depressive episode.
Patients were excluded if they had significant suicidal risk, some severe
co-occurring psychiatric or cognitive disorders, and/or unstable or
significant medical conditions, as described in the Supplemental
Methods.
Analyses were conducted for two pre-specified cohorts. The intent-
to-treat cohort included patients who met eligibility criteria. The per-
protocol cohort additionally excluded patients who had a score of< 14
on the HAM-D17 at baseline to ensure the exclusion of patients with
mild depression. Patients also were excluded if there were protocol
violations or if the clinician did not view the electronic test report prior
to the baseline visit (guided-care arm only).
2.4. Medication congruence with pharmacogenomic testing
Consistent with previous studies, prescribed medications were
considered congruent with the pharmacogenomic test if they were in the
‘use as directed’ or ‘use with caution’ report categories (Altar et al.,
2015; Winner et al., 2015). Although medications in the ‘use with
caution’ category were subject to moderate gene-drug interactions, they
were considered congruent because minor clinical modifications (e.g.
dose adjustment) were predicted to make medications in this category
safe and/or effective. Medications were considered incongruent if they
were in the ‘use with increased caution and with more frequent mon-
itoring’ category.
A post-hoc analysis evaluated the sub-set of patients in both study
arms taking ≥1 incongruent medication prior to medication changes at
baseline. Outcomes were evaluated for patients who changed to con-
gruent medications by week 8 versus those who remained on incon-
gruent medications. Patients were considered as taking congruent
medications if none of their prescribed medications were incongruent.
For TAU, this included patients who were incidentally switched to
congruent medications without the aid of the pharmacogenomic test
report.
2.5. Side effects
Patient-reported side effects were assessed as the mean number of
side effects and proportion of patients reporting side effects according
to study arm and baseline medication congruence. Only side effects
with a probability of causal link to medication (e.g. categorized as
likely, probably, possibly, or definitely relating to medication) were
included.
2.6. Statistical analysis
Analyses were performed according to a pre-specified statistical
analysis plan. The primary outcome was symptom improvement at week
8 in the per-protocol cohort, as measured by the percent change in
HAM-D17 (blinded central rater) from baseline. Secondary outcomes
included response and remission at week 8 according to HAM-D17.
Patient outcomes were further assessed by QIDS-C16 (blinded site
rater), and PHQ-9 (blinded patient rated). Response was defined as
≥50% decrease at week 8 in the assessment of interest (HAM-D17,
QIDS-C16 or PHQ-9) from baseline. Remission was defined as having a
score of ≤7 for HAM-D17, ≤5 for QIDS-C16, and< 5 for PHQ-9.
Patient demographics and clinical characteristics were assessed
using descriptive statistics. The severity of depression was categorized
according to HAM-D17 scores: 0-7, normal; 8-13, mild depression; 14-
18, moderate depression; 19-22, severe depression; ≥23, very severe
depression. A post-hoc moderator analysis was performed to determine
whether the following baseline variables significantly affected the pri-
mary outcome: age, gender, HAM-D17 score, genetic congruence of
medications, pharmacogenomic report category, number of failed
medications, race (Caucasian, non-Caucasian), and ethnicity (Hispanic,
non-Hispanic).
Analyses were performed for patients who completed the study
through week 8. A Mixed Model for Repeated Measures (MMRM) was
used for percentage change from baseline in HAM-D17, QIDS-C16, and
PHQ-9 analyses, and generalized linear mixed model was used for re-
sponse and remission analyses. T-tests were used to obtain two-sided p-
values for study arms and comparison groups, where values≤ 0.05
were considered statistically significant. Analyses were performed with
SAS software (version 9.4) or JMP 13 (SAS Institute).
3. Results
3.1. Cohort description
Overall, 2004 patients were screened for inclusion in this study;
1799 met eligibility criteria and were randomized to TAU or guided-
care after pharmacogenomic testing (Supplemental Fig. 1). After ran-
domization, an additional 258 patients were excluded because they
didn't meet the eligibility criteria at baseline or were lost to follow-up
prior to baseline. A total of 1541 patients completed the baseline visit
and were included in the final intent-to-treat cohort. For the per-pro-
tocol cohort, an additional 143 patients were excluded; 101 patients
had a baseline HAM-D17 score< 14 (below mild depression) and 42
patients had protocol violations. The final per-protocol cohort included
1398 patients (717 patients in TAU, 681 patients in guided-care).
Although a minimum of one failed medication trial was required for
enrollment, the mean number of failed medications was 3.51 (Table 1).
The mean HAM-D17 score at baseline was 21.28, with a relatively equal
distribution of patients with moderate (392/1398, 28.0%), severe
(493/1398, 35.3%), or very severe (513/1398, 36.7%) depression
(Table 1). General anxiety disorder was the most common psychiatric
comorbidity. The mean age was 47.5 years and the majority (987/1398,
70.6%) of patients were female (Table 1). There were no substantial
differences in demographics or disease by treatment arm (Table 1) or
between the per-protocol and intent-to-treat cohorts (Supplemental
Table 2).
At baseline, only 18.3% (256/1398) of patients were taking medi-
cations in the most severe report category (‘use with increased caution
and with more frequent monitoring’). The majority of patients were
taking medications in the ‘use as directed’ (357/1398, 25.5%) or ‘use
with caution’ (575/1398, 41.1%) report categories (Table 1). The re-
maining 15.0% (210/1398) of patients were not taking any medications
included on the pharmacogenomic test report at baseline. There were
no substantial differences between the individual gene phenotypes as
determined by the pharmacogenomic test by study arm (Supplemental
Table 3). Selective serotonin reuptake inhibitors (SSRIs) were the most
commonly prescribed psychotropic medications at baseline for both the
guided-care arm and TAU, accounting for nearly half of all prescribed
medications (Supplemental Table 4).
In the per-protocol cohort, 1167 patients completed the study
through the blinded week 8 endpoint (607 patients in TAU, 560
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patients in the guided-care arm). A total of 913 patients completed the
study through week 24, with weeks 12–24 being unblinded (456 pa-
tients in TAU, 457 patients in the guided-care arm; Supplemental
Fig. 1). There were no substantial differences in the baseline demo-
graphics according to study arm for those who completed week 8
(Supplemental Table 5). Use of SSRIs decreased from baseline to week 8
while use of other psychotropic medications increased (Supplemental
Table 4).
3.2. Symptom improvement, response, and remission
At week 8, there was a 27.2% decrease in HAM-D17 scores in the
guided-care arm compared to a 24.4% decrease in TAU (Fig. 1). This
difference in the primary outcome was not significant (p= 0.107).
Differences in the key secondary outcomes of response and remission
were positive and significant. The response rate among patients in the
guided-care arm was 26.0% (146/560) at week 8, which was sig-
nificantly higher than in TAU [19.9% (121/607), p= 0.013; Fig. 1].
Similarly, the rate of remission among patients in the guided-care arm
(15.3%, 86/560) was significantly higher than in TAU [10.1% (61/
607), p= 0.007; Fig. 1]. Although overall improvement was modest,
this represents a 30% improvement in response, and 50% improvement
in remission among these difficult-to-treat patients in the guided-care
arm compared to TAU.
A moderator analysis was performed to assess whether any clinical
or demographic variables affected treatment performance for the pri-
mary outcome of symptom improvement. There were no significant
moderation factors (Table 2), supporting that the primary outcome
according to study arm was not dependent on the other factors eval-
uated.
Continuous changes in HAM-D17 score from baseline to week 8
were assessed to evaluate why the continuous endpoint of symptom
improvement did not reach statistical significance while the categorical
endpoints (response, remission) were significant. This revealed that the
distribution of continuous HAM-D17 score improvement from baseline
to week 8 was shifted towards extreme improvement (≥50% decrease
in HAM-D17; definition of response) in the guided care arm and to-
wards modest improvement in TAU (Supplemental Fig. 2). As a result,
the mean HAM-D17 improvement was similar for both study arms
(Δ2.8%, p=0.107) while the proportion of patients with extreme im-
provement in the guided-care arm drove a significant difference in the
rate of response and remission.
Symptom improvement, response, and remission based on HAM-
D17 in the intent-to-treat cohort (Fig. 2) were similar to the per-pro-
tocol cohort (Fig. 1). Therefore, outcomes based on secondary rating
scales (QIDS-C16, blinded-site rater; PHQ-9, blinded-patient rated)
were assessed in the intent-to-treat cohort. At week 8, symptom im-
provement (QIDS-C16 p=0.182; PHQ-9 p=0.036), response (QIDS-
Table 1
Baseline demographics for patients in the per-protocol cohort who completed the baseline visit.
Treatment Arm Total (N=1398)
Characteristic TAU (N=717) Guided–Care (N=681)
N % N % N %
Age Group
18–34 years 158 22.0 162 23.8 320 22.9
35–49 years 192 26.8 200 29.4 392 28.0
50–64 years 266 37.1 235 34.5 501 35.8
65 years and over 101 14.1 84 12.3 185 13.2
Sex
Female 498 69.5 489 71.8 987 70.6
Male 219 30.5 192 28.2 411 29.4
Ethnicity
Hispanic or Latino 54 7.5 57 8.4 111 7.9
Not Hispanic or Latino 663 92.5 624 91.6 1287 92.1
Race
White 589 82.1 538 79.0 1127 80.6
Black 94 13.1 114 16.7 208 14.9
Asian 17 2.4 12 1.8 29 2.1
American Indian or Alaska Native 3 0.4 5 0.7 8 0.6
Native Hawaiian or Other Pacific Islander 0 0 1 0.1 1 0.1
Other or Multiple 14 2.0 11 1.6 25 1.8
Depression Category
Moderate (HAM-D17 14-18) 187 26.1 205 30.1 392 28.0
Severe (HAM-D17 19-22) 264 36.8 229 33.6 493 35.3
Very Severe (HAM-D17≥23) 266 37.1 247 36.3 513 36.7
Psychiatric Comorbidities
General anxiety disorder 96 13.4 116 17.0 212 15.2
Panic disorders/social phobia 108 15.1 104 15.3 212 15.2
Post-traumatic stress disorder 32 4.5 36 5.3 68 4.9
Pharmacogenomic Report Categorya
Use as Directed 181 25.2 176 25.8 357 25.5
Use with Caution 295 41.1 280 41.1 575 41.1
Use with Increased Caution and with More Frequent Monitoring 138 19.2 118 17.3 256 18.3
Not Applicableb 103 14.4 107 15.7 210 15.0
Mean (SD) Min, Max Mean (SD) Min, Max Mean (SD) Min, Max
Age (years) 48.0 (14.5) 18, 85 46.9 (14.5) 18, 90 47.5 (14.5) 18, 90
HAM-D17 Score 21.4 (4.22) 14, 35 21.1 (4.20) 14, 37 21.3 (4.21) 14, 37
Failed Medication Trials 3.53 (3.01) 1, 34 3.48 (3.09) 1, 25 3.51 (3.05) 0, 34
a For patients taking more than one medication at baseline, the most severe report category is included.
b Includes patients not taking any medications included on the pharmacogenomic test report at baseline.
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C16 p=0.285; PHQ-9 p= 0.002), and remission (QIDS-C16
p=0.014; PHQ-9 p=0.066) were improved in the guided-care arm
relative to TAU, though not all differences were significant (Fig. 2).
Patient outcomes were evaluated over the full 24-week study period
in the guided-care arm of the per-protocol cohort to assess the longer-
term impact of pharmacogenomic testing. Sustained decreases on the
HAM-D17 rating scale demonstrated durable and continuing symptom
improvement after unblinding, with HAM-D17 scores decreasing by
42.5% at week 24 relative to baseline (Fig. 3). This represents a 50%
improvement from week 8 outcomes. The rates of response and re-
mission increased by 70% and 100%, respectively, from week 8 to week
24. Specifically, 44.3% (203/457) of patients experienced response and
31.1% (142/457) of patients experienced remission at week 24 (Fig. 3).
3.3. Congruence with pharmacogenomic testing and outcomes
Prior to treatment changes at baseline, 79.4% (456/574) of patients
in the guided-care arm and 77.5% (476/614) of patients in TAU were
prescribed medications that were congruent with the pharmacoge-
nomic test report (Supplemental Fig. 3). The proportion of patients who
were prescribed congruent medications at week 8 increased to 91.2%
(508/557) for the guided-care arm and remained relatively unchanged
in TAU (Supplemental Fig. 3). As already noted, the prescription of
genetically congruent medications in TAU was incidental and not based
on the pharmacogenomic test report.
One of the greatest potential utilities of the pharmacogenomic test is
for patients taking incongruent medications, i.e., those with a poten-
tially deleterious gene-drug interaction. An analysis of patients in both
arms who entered the study on incongruent medications was per-
formed. At baseline, patients on incongruent (N=213) and congruent
medications (N=805) had similar mean HAM-D17 scores (21.19 and
21.18, respectively) and number of failed medication trails (3.77 and
3.59, respectively) (Supplemental Table 6). The analysis of patients on
incongruent medications at baseline showed that outcomes were sig-
nificantly improved among those who switched to a congruent medi-
cation by week 8. There was a 33.5% decrease in HAM-D17 scores
among patients who switched to congruent medications compared to
21.1% among those who remained on incongruent medications
(p= 0.002; Fig. 4). In addition, this analysis showed statistically sig-
nificant improvements among patients on congruent versus incongruent
medications at week 8 in the rates of response [28.5% (22/77) versus
16.7% (23/136), p= 0.036] and remission [21.5% (17/77) versus
8.5% (12/136), p= 0.007].
3.4. Side effects
There were no statistically significant differences between the
guided-care arm and TAU regarding the mean number of side effects at
week 8 (0.243 versus 0.237, p=0.855) or the proportion of patients
who experienced side-effects [15.6% (88/560) versus 15.3% (93/607),
p= 0.881; Supplemental Table 7]. When the proportion of patients
who were taking incongruent medications at baseline was evaluated
separately, those who switched to congruent medications by week 8
had a significantly lower mean number of side effects compared to
those who remained incongruent (0.065 versus 0.242, p=0.002;
Supplemental Table 7). Significantly fewer patients who switched to
congruent medications experienced side effects compared to those who
did not [6.5% (5/77) versus 16.5% (22/136), p= 0.045].
4. Discussion
Data from this GUIDED trial help clarify a number of concerns and
applications regarding the utility of pharmacogenomic testing in pa-
tients with difficult-to-treat MDD. The primary outcome of symptom
improvement was not significantly different between the study arms.
While it is possible this result illustrates real-world clinical outcomes, it
may also reflect the fact that three-quarters of patients in TAU were
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Fig. 1. Patient outcomes at week 8 in the pharmacogenomics guided-care arm (n=560) compared to treatment as usual (n= 607). Outcomes were evaluated using
the HAM-D17 depression rating scales.
Table 2
Moderator analysis evaluating the impact of clinical variables at baseline on the
primary outcome (symptom improvement by treatment arm).
Variable t-value p-Valuea
Ageb −0.86 0.3877
Gender −0.31 0.7531
HAM-D17 Score at Baselineb 1.00 0.3168
Congruency of Baseline Medications (Congruent,
Incongruent)
1.08 0.2802
PGx Report Category of Baseline Medicationsd 0.65c 0.5204
Number of Failed Medications at Baselineb 0.99 0.3221
Race (Caucasian, non-Caucasian) −0.75 0.4538
Ethnicity (Hispanic, non-Hispanic) −1.63 0.1033
a The percentage change in HAM-D17 at week 8 from baseline was analyzed
using separate models that included treatment arm, baseline HAM-D17 score,
the variable of interest (e.g., age), and treatment arm-by-variable of interest.
Reported p-values are from the tests of moderation effect - treatment arm-by-
variable of interest. P-values less than 0.05 indicate a significant effect of the
clinical variable on treatment arms.
b Evaluated as a continuous variable.
c F-test statistic.
d Report categories were ‘use as directed’, ‘use with caution’, or ‘use with
increased caution and with more frequent monitoring’.
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incidentally prescribed medications that were congruent with the test
report at baseline and throughout the study. Because a key potential
clinical application of pharmacogenomics is to identify patients whose
treatment resistance may be linked to genetically incongruent medi-
cations (Hall-Flavin et al., 2013; Winner, J.G. et al., 2013; Winner et al.,
2015), the overall impact of pharmacogenomic testing in this trial may
have been diluted by the large proportion of patients already taking
genetically congruent medications. When only patients taking geneti-
cally incongruent medications at baseline were assessed, symptom
improvement was significantly better among patients who switched to
congruent medications at week 8 compared to those who remained on
incongruent medications (Δ=12.4%, p= 0.002).
Importantly, combined and weighted, multi-gene pharmacogenomic
testing for patients with treatment resistance significantly increased the
likelihood of achieving response and remission over TAU medication
selection strategies. Larger, controlled studies still need to be performed
for those receiving their initial treatment. The modest rates of response
and remission reported here are consistent with previous reports of
patients with treatment resistant depression (Rush et al., 2006b) and
again highlight the significant clinical challenges in this difficult-to-
treat population. As such, the modest but important improvements in
response and remission for patients in the guided-care arm are clinically
meaningful. In addition, sustained remission is the ideal objective of
treatment for those with MDD (Armstrong, 2011; Cleare et al., 2015;
Lam et al., 2016; Rush et al., 2006a); however, most studies on phar-
macogenomics have ended after 8 weeks – the typical duration of acute
phase treatment. In this trial, the rate of remission doubled from week 8
to week 24 among patients in the guided-care arm. These data suggest
that improved patient outcomes achieved with pharmacogenomic
testing are durable in the maintenance therapy setting.
The pharmacogenomic test used in this study evaluated gene-drug
interactions that may impact medication safety. As such, changes from
incongruent to congruent medications should reduce side effect burden.
There were no significant differences in side effect burden in the full
study cohort. In addition, not all gene-drug interactions were predicted
to impact drug safety. However, when the subset of patients taking
incongruent medications at baseline were evaluated, side effect burden
was significantly reduced when patients switched to congruent medi-
cations.
The existing and growing array of pharmacogenomic tests poses
clinical implementation challenges. There are several approaches to
pharmacogenomic testing and the clinical utility of each approach must
be subject to individual (Bousman and Dunlop, 2018) and Center for
Disease Control assessments of robust validation (Prevention, 2010).
Previous studies have shown that single-gene testing is often ineffective
at improving patient outcomes (EGAPP Working Group, 2007) while
studies on multi-gene testing have been mixed. However, several small
(< 325 patients) randomized controlled trials have shown that anti-
depressant selection guided by multi-gene pharmacogenomic testing
improved outcomes among patients with MDD (Bradley et al., 2018;
Perez et al., 2017; Singh, 2015). The largest effect sizes reported to date
emerged from a post-hoc analysis of the subset of patients with severe
depression (n= 93) in a randomized controlled trial, though no results
were reported for the full study (Bradley et al., 2018).
The clinical utility of the pharmacogenomic test used in this report
has been evaluated in three previous studies (Hall-Flavin et al., 2013;
Hall-Flavin et al., 2012; Winner, J.G. et al., 2013). A small, pilot,
blinded, randomized controlled trial provided the basis for the design of
the current study (Winner, J.G. et al., 2013). While underpowered to
detect true differences between groups, outcomes improved in the di-
rection of the guided-care group (Winner, J.G. et al., 2013). In addition,
treatment guided by pharmacogenomics resulted in significantly better
symptom improvement in two open-label, non-randomized trials (Hall-
Flavin et al., 2012, 2013). The current randomized, controlled trial
demonstrated the clinical utility of pharmacogenomic testing in 1167
patients with MDD whose depression ranged from moderate to very
severe. While this study adds to the body of evidence on combined and
weighted, multi-gene pharmacogenomics, the conclusions from this
trial cannot be generalized to the entire array of pharmacogenomic
tests.
This study had several strengths. First, the study design is in line
with the recent FDA draft guidance for MDD trials, which recommends
evaluation of outcomes for patients with treatment resistant depression
(≥1 medication failure) in the short-term (6–8 weeks) and main-
tenance (≥6 months) settings using HAM-D17 (U.S. Food and Drug
Administration, 2018). Second, the diversity of the study cohort mirrors
the varied clinical settings in which MDD is treated. Patients were in-
cluded from both academic and community sites and treating clinicians
included psychiatrists and primary care providers. Third, the active
treatment approach employed in both study arms models clinical
practice and provides a meaningful evaluation of clinical utility. This
also represents a significant hurdle in demonstrating efficacy due to the
expected range of response to antidepressants in both arms. A sys-
tematic review of phase III antidepressant approval studies over 20
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years, where active treatment was compared to placebo, shows that
response and remission were significantly improved in only 30% and
13% of trials, respectively (Supplemental Table 8). Pharmacogenomic-
guided care surmounted the challenge of a comparison to an active
control condition and achieved greater response and remission rates in
this trial.
There were limitations of this study. First, the treating clinician was
not blinded to study arm. This was necessitated by the ethical issues of
mandating prescribed medications in order to blind clinicians. To mi-
tigate this limitation, central raters, site raters, and patients were
blinded to study arm until after week 8. In addition, the primary as-
sessment was performed by a blinded-central rater who had no inter-
action with the clinician. Second, the majority of the cohort was
Caucasian. While this may limit the generalizability of these findings,
the ancestry distribution reported here mimics the US population (US
Census Bureau, 2016). Additional evaluation of more diverse popula-
tions may be warranted. Third, the per-protocol cohort only included
patients with moderate to severe MDD, based on HAM-D17 score. While
the intent-to-treat cohort included patients with more mild depression
according to HAM-D17 score, the primary results may not be general-
izable for patients with mild depression. Finally, the impact of poly-
pharmacy on patient outcomes was not evaluated and is an area for
future study. However, any confounding effects of polypharmacy would
likely be biased towards the null hypothesis, as medications taken to
treat non-MDD conditions would impact patient outcomes in both arms.
Despite these potential confounding effects, improved patient outcomes
were observed in the guided-care arm over TAU.
In summary, this randomized controlled trial found that weighted
and combined multi-gene pharmacogenomic testing significantly in-
creased clinical response and remission rates for patients with MDD in
the guided-care arm versus TAU. Pharmacogenomic testing pre-
dominantly helped those patients whose treatment resistance may have
been related to genetically incongruent medications. Without testing,
patients and clinicians are unaware of potential ongoing gene-drug
interactions. These results from the GUIDED trial indicate that phar-
macogenomic testing is effective in improving response and remission
rates among those with prior treatment resistance, particularly for pa-
tients who are treated with medications that are incongruent with their
genetic profile.
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